Benzinga | Jan 28, 2021 07:11AM EST

Truist Securities Initiates Coverage On NeoGenomics with Buy Rating, Announces Price Target of $65

Truist Securities analyst Sandy Draper initiates coverage on NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $65.